204 related articles for article (PubMed ID: 32941854)
1. Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy.
Danek PJ; Wójcikowski J; Daniel WA
Toxicol Appl Pharmacol; 2020 Nov; 406():115239. PubMed ID: 32941854
[TBL] [Abstract][Full Text] [Related]
2. The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions.
Danek PJ; Wójcikowski J; Daniel WA
Pharmacol Rep; 2020 Dec; 72(6):1685-1694. PubMed ID: 32279279
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
4. Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4.
Danek PJ; Basińska-Ziobroń A; Wójcikowski J; Daniel WA
Pharmacol Rep; 2021 Feb; 73(1):303-308. PubMed ID: 32888176
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study.
Basińska-Ziobroń A; Daniel WA; Wójcikowski J
Pharmacol Rep; 2015 Dec; 67(6):1178-82. PubMed ID: 26481538
[TBL] [Abstract][Full Text] [Related]
6. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms.
Danek PJ; Kuban W; Daniel WA
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445153
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes).
Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP
Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472
[TBL] [Abstract][Full Text] [Related]
9. Iloperidone, asenapine and lurasidone: a primer on their current status.
Tarazi FI; Stahl SM
Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
[TBL] [Abstract][Full Text] [Related]
10. Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers.
Stassinos G; Klein-Schwartz W
Clin Toxicol (Phila); 2018 May; 56(5):355-359. PubMed ID: 28992737
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
12. Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies.
Garcia M; Rager J; Wang Q; Strab R; Hidalgo IJ; Owen A; Li J
In Vitro Cell Dev Biol Anim; 2003; 39(7):283-7. PubMed ID: 14599235
[TBL] [Abstract][Full Text] [Related]
13. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Citrome L
Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
[TBL] [Abstract][Full Text] [Related]
14. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study.
Wójcikowski J; Daniel WA
Pharmacol Rep; 2009; 61(5):851-8. PubMed ID: 19904008
[TBL] [Abstract][Full Text] [Related]
15. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.
Halladay JS; Wong S; Khojasteh SC; Grepper S
J Pharmacol Toxicol Methods; 2012; 66(3):270-5. PubMed ID: 22809809
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
17. The Atypical Antipsychotic Lurasidone Affects Brain but Not Liver Cytochrome P450 2D (CYP2D) Activity. A Comparison with Other Novel Neuroleptics and Significance for Drug Treatment of Schizophrenia.
Danek PJ; Daniel WA
Cells; 2022 Nov; 11(21):. PubMed ID: 36359909
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450.
Chiangsom A; Lawanprasert S; Oda S; Kulthong K; Luechapudiporn R; Yokoi T; Maniratanachote R
Drug Metab Pharmacokinet; 2016 Jun; 31(3):210-7. PubMed ID: 27212065
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
20. Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system.
Pimkaew P; Küblbeck J; Petsalo A; Jukka J; Suksamrarn A; Juvonen R; Auriola S; Piyachaturawat P; Honkakoski P
Toxicol In Vitro; 2013 Sep; 27(6):2005-12. PubMed ID: 23850985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
